Centocor Ortho Biotech News
Most Popular Centocor Ortho Biotech Story
FDA rejects Yondelis-Doxil combo for ovarian cancer
The FDA has rejected Centecor Ortho Biotech's application to market Doxil in combination with Zeltia's Yondelis (trabectedin) as a treatment for ovarian cancer. Following a panel recommendation Read more...
Latest Headlines
- May 31, 2011
- June 1, 2010
- September 10, 2009
- June 4, 2009
- April 24, 2009
- September 18, 2008
- June 18, 2008
- October 4, 2007
- September 7, 2007
- August 28, 2007
- January 7, 2007
- January 3, 2007
- January 2, 2007
- October 26, 2006
- August 13, 2006
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
